Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvativir in COVID-19 Patients
NCT05445089Phase 3Completed
- Sponsor
- Instituto Venezolano de Investigaciones Científicas
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Carvativir Group with Placebo Group (2 arms). Primary endpoints: Mortality Rate Among COVID-19 Patients at 15 days, Interleukin 6 at 15 days and 4 more. Started Aug 2020; status: completed.
02
Drugs
Carvativir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05445089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05445089.